The COP Regimen is not a Feasible Treatment for Advanced, Refractory Chronic Lymphocytic Leukemia

References

• Rozman C., Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 1995; 333: 1052–1057
   PubMed Web of Science ®Google Scholar
• Catovsky D., Fooks J., Richards S. The UK Medical Research Council CLL trials 1 and 2. Nouv. Rev. Fr. Hematol. 1988; 30: 423–427
   PubMedGoogle Scholar
• Catovsky D., Richards S., Fooks J., Hamblin T. J. CLL trials in the United Kingdom. The Medical research Council CLL trials 1, 2 and 3. Leuk. Lymphoma 1991; 5: 105–112, (Suppl.)
   PubMed Web of Science ®Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 1990; 75: 1422–1425
   PubMed Web of Science ®Google Scholar
• Montserrat E., Alcala A., Parody R., Domingo A., Garcia-Conde J., Bueno J., Ferran C., Sanz M. A., Giralt M., Rubio D., Anton I., Estape J., Rozman C. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 1985; 56: 2369–2375
   PubMed Web of Science ®Google Scholar
• Raphael B., Andersen J. W., Silber R., Oken M., Moore D., Bennett J., Bonner H., Hahn R., Knospe W. H., Mazza J., Glick J. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J. Clin. Oncol. 1991; 9: 770–776
   PubMed Web of Science ®Google Scholar
• Liepman M., Votaw M. L. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978; 41: 1664–1669
   PubMed Web of Science ®Google Scholar
• French Cooperative Group on Chronic Lymphocytic Leukemia. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk. Lymphoma 1994; 13: 449–456
   PubMed Web of Science ®Google Scholar
• Hansen M. M., Andersen E., Christensen B. E., Cristiansen I., Geisler G., Kristensen D., Jensen K. B., Junker P. CHOP versus prednisolone + chlorambucil in chronic lymphocytic leukemia: Preliminary results of a randomized multicenter study. Nouv. Rev. Fr. Hematol. 1988; 30: 433–436
   PubMedGoogle Scholar
• Kimby E., Mellstedt H. Chlorambucil/prednisone versus CHOP in symptomatic chronic lymphocytic leukemias of B-cell type. A randomized trial. Leuk. Lymphoma 1991; 5: 93–96, (Suppl.)
   PubMed Web of Science ®Google Scholar
• Binet J. L., Auquier A., Dighiero G., Chastang C., Piguet J., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M. T., Monconduit M., Belabbes S., Gremy F. A new prognostic classification of chronic lymphocytic leukemia from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• International Workshop on Chronic Lymphocytic Leukemia. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging, and response criteria. Ann. Intern. Med. 1989; 110: 236–238
   PubMed Web of Science ®Google Scholar
• Oken M. M., Kaplan E. K. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treatm. Rep. 1979; 63: 441–447
   PubMedGoogle Scholar
• Juliusson G., Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-Chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: No acquired resistance. Leuk. Lymphoma 1994; 13: 75–80
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Beran M., Robertson L. E., Roller C., Lemer S., Keating M. J. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 1995; 86: 1296–1300
   Web of Science ®Google Scholar
• Molica S. High-dose dexamethasone in refractory B-cell chronic lymphocytic leukemia. Am. J. Hematol. 1994; 47: 324
   Web of Science ®Google Scholar
• Friedenberg W. R., Anderson J., Wolf B. C., Cassileth P. A., Oken M. Modified vincristine, doxorubicin, and dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic leukemia. Cancer 1993; 71: 2983–2989
   PubMed Web of Science ®Google Scholar
• Keating M. J., Scouros M., Murphy S., Kantarjian H., Hester J., McCredie K. B., Hersh E. M., Freireich E. J. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157–164
   PubMed Web of Science ®Google Scholar
• Grever M. R., Kopecky K. J., Coltman C. A., Files J. C., Greenberg B. R., Hutton J. J., Talley R., Von Hoff D. D., Balcerzak S. P. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 1988; 30: 457–459
   PubMedGoogle Scholar
• Hiddemann W., Rottmann R., WÖRmann B., Thiel A., Essink M., Ottensmeier C., Freund M., BÜChner T., Vande Loo J. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Ann. Hematol. 1991; 63: 1–4
   PubMed Web of Science ®Google Scholar
• Catovsky D., Matutes E., Emmett E., Hickish T., Mills M. Fludarabine monophosphate for the treatment of refractory chronic lymphocytic leukemia (CLL), prolymphocyte leukemia (PLL) and low/intermediate grade lymphoma in leukaemic phase. 24th Congress of the International Society of Haematology. 1992; 14, Abstract Book
   Google Scholar
• Bergmann L., Fenchel K., Jahn B., Mitrou P. S., Hoelzer D. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann. Oncol. 1993; 4: 371–375
   PubMed Web of Science ®Google Scholar
• Keating M. J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Koller C., Beran M., Freireich E. J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Lauria F., Rondelli D., Benfenati D., Raspadori D., Bocchia M., Gozzetti A., Cavo M., Cirio T. M., Zaja F., Russo D., Fanin R., Galieni P., Algeri R., Fiacchini M., Tura S. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur. J. Haematol. 1993; 51: 93–97
   PubMed Web of Science ®Google Scholar
• Gillis S., Dann E. J., Cass Y., Rochlemer R., Polliack A. Activity in refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma—the Jerusalem experience. Leuk. Lymphoma 1994; 15: 173–175
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma 1994; 133–138, Suppl.
   PubMedGoogle Scholar
• O'Brien S., Kantarjian H., Estey E., Koller C., Robertson B., Beran M., Andreeff M., Pierce S., Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N. Engl. J. Med 1994; 330: 319–322
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Hakimian D., Zanzig C., Hogan D. K., Rademaker A., Rose E., Variakojis D. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 1995; 13: 983–988
   PubMed Web of Science ®Google Scholar